SAN DIEGO--(BUSINESS WIRE)--Mar. 7, 2019--
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery
and diabetes technology company, today announced that it is now
registered as an approved vendor of insulin pumps and supplies under the
Assistive Devices Program (ADP) in Ontario, Canada. The t:slim X2
insulin pump features Dexcom G5® Mobile continuous glucose monitoring
(CGM) integration,1 making it the only CGM-integrated insulin
pump approved in Canada for making daily diabetes treatment decisions
“This registration is meaningful, as approximately 40 percent of people
living with type 1 diabetes in Canada reside in Ontario and are now able
to obtain reimbursement for the t:slim X2 insulin pump,” said John
Sheridan, president and CEO of Tandem Diabetes Care. “We’ve seen a high
level of interest from people with diabetes in Canada, where insulin
pump options have been limited in recent years. By reducing a financial
barrier, this registration provides more people access to our exciting
technology as a new option for insulin therapy management.”
The simple-to-use t:slim X2 insulin pump includes advanced features like
a large color touchscreen, rechargeable battery, USB connectivity and
watertight construction (IPX7)3. As the only insulin pump
integrated with Dexcom G5 Mobile CGM, dynamic glucose data can be easily
accessed and shared using a compatible mobile device.4 The
t:slim X2 pump is up to 38 percent smaller than other insulin pumps and
holds up to 300 units of insulin.5
The t:slim X2 insulin pump is now covered in Ontario, Manitoba, and
Saskatchewan, and has been approved for listing on the Non-Insured
Health Benefits (NIHB) program which provides coverage to the First
Nations and Inuit population. Tandem has now secured coverage for nearly
half of all Canadians living with type 1 diabetes.
Ontario residents interested in determining ADP eligibility and applying
for coverage for a t:slim X2 insulin pump can get started at https://www.ontario.ca/page/insulin-pumps-and-diabetes-supplies.
For additional information on the t:slim X2 insulin pump or to begin
the order process, call (833) 509-3958 or visit www.tandemdiabetes.ca.
Diabetes in Canada
According to Diabetes Canada (www.diabetes.ca),
there are more than 3.6 million Canadians living with diabetes and
approximately 10 percent have type 1 diabetes.6 Insulin pumps
and diabetes supplies are a covered benefit for qualifying recipients of
disability tax credit, assistive devices programs, and qualifying
expenses for registered disability savings plans offered in various
forms across Canadian provinces.7
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. Tandem takes an innovative, user-centric approach to the
design, development and commercialization of products for people with
diabetes who use insulin. Tandem manufactures and sells the t:slim X2
insulin pump, which features integrated continuous glucose monitoring.
Tandem is based in San Diego, California.
Tandem Diabetes Care and t:slim X2 are trademarks, registered
trademarks, and/or the subject of a pending trademark application in the
U.S. and other territories worldwide. Dexcom and Dexcom G5 are
registered trademarks of Dexcom, Inc. All other trademarks are the
property of their respective owners.
Forward Looking Statement
This press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
relate to, among other things, the anticipated coverage for the t:slim
X2 pump in Canada and our ability to adhere to coverage requirements and
sustain coverage eligibility under the stated health programs . These
statements are subject to numerous risks and uncertainties, including
our ability to recruit, hire and train new personnel to support our
operations in Canada, establish policies and procedures to comply with
the coverage requirements under applicable health programs, manufacture
commercial quantities of a new version of the t:slim X2 pump for the
Canadian market, as well as other risks identified in our most recent
Annual Report on Form 10-K, and other documents that we file with the
Securities and Exchange Commission. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date of this release. Tandem undertakes no obligation to update
or review any forward-looking statement in this press release because of
new information, future events or other factors.
Dexcom G5 Mobile CGM System sold separately. The Dexcom G5 Mobile
CGM transmitter can only be paired with one medical device (either a
Dexcom receiver or t:slim X2 insulin pump) and one consumer device
(phone or tablet) at the same time.
If glucose alerts and CGM readings do not match symptoms or
expectations,or you are taking medications containing
acetaminophen, you should perform a fingerstick to confirm your
blood glucose level. Aminimum of two fingersticks a day
are required for calibration.
Tested to a depth of 3 feet for 30 minutes.
Following your shared data requires the Dexcom Follow app.
Compatible mobile devices are listed at: Dexcom.com/compatibility
38 percent smaller than MiniMed 630G and 670G and at least 28
percent smaller than MiniMed 530G, Animas Vibe and Omnipod System.
Data on file, Tandem Diabetes Care.
Estimated diabetes statistics in Canada are generated by the
Canadian Diabetes Cost Model; 2015.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005783/en/
Source: Tandem Diabetes Care, Inc.
Tandem Diabetes Care Contact Information:
Sabicer, +1 714-907-6264
Susan Morrison, +1 858-366-6900 x7005